PRAXIS PRECISION MEDICINES I (PRAX) Forecast, Price Target & Analyst Ratings

NASDAQ:PRAX • US74006W2070

Current stock price

324.2 USD
+5.37 (+1.68%)
At close:
324.2 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRAXIS PRECISION MEDICINES I (PRAX).

Forecast Snapshot

Consensus Price Target

Price Target
$646.92
+ 99.54% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 13, 2026
Period
Q1 / 2026
EPS Estimate
-$3.64
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.73%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$646.92
Upside
+ 99.54%
From current price of $324.20 to mean target of $646.92, Based on 22 analyst forecasts
Low
$131.30
Median
$565.08
High
$1,307.25

Price Target Revisions

1 Month
5.58%
3 Months
37.12%

Price Target Summary

22 Wall Street analysts provided a forecast for the next 12 months for PRAX. The average price target is 646.92 USD. This implies a price increase of 99.54% is expected in the next year compared to the current price of 324.2.
The average price target has been revised upward by 37.12% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PRAX Current Analyst RatingPRAX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

PRAX Historical Analyst RatingsPRAX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
82.73%
PRAX was analyzed by 22 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PRAX.
In the previous month the buy percentage consensus was at a similar level.
PRAX was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-14NeedhamReiterate Buy -> Buy
2026-04-07HC Wainwright & Co.Reiterate Buy -> Buy
2026-04-06BTIGReiterate Buy -> Buy
2026-02-24Wolfe ResearchInitiate Outperform
2026-02-20WedbushMaintains Underperform -> Underperform
2026-02-20Wells FargoMaintains Equal-Weight -> Equal-Weight
2026-02-20Truist SecuritiesMaintains Buy -> Buy
2026-02-20BairdMaintains Outperform -> Outperform
2026-02-10GuggenheimMaintains Buy -> Buy
2026-02-04NeedhamMaintains Buy -> Buy
2026-02-02Wells FargoInitiate Equal-Weight
2026-01-30HC Wainwright & Co.Maintains Buy -> Buy
2026-01-28Piper SandlerMaintains Overweight -> Overweight
2026-01-12WedbushMaintains Underperform -> Underperform
2025-12-29BTIGMaintains Buy -> Buy
2025-12-15OppenheimerMaintains Outperform -> Outperform
2025-12-09GuggenheimMaintains Buy -> Buy
2025-12-09JefferiesMaintains Buy -> Buy
2025-12-08TD CowenMaintains Buy -> Buy
2025-12-08BTIGMaintains Buy -> Buy
2025-12-08NeedhamMaintains Buy -> Buy
2025-12-08Truist SecuritiesMaintains Buy -> Buy
2025-12-08HC Wainwright & Co.Reiterate Buy -> Buy
2025-12-05NeedhamMaintains Buy -> Buy
2025-12-05WedbushMaintains Underperform -> Underperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 13, 2026
Period
Q1 / 2026
EPS Estimate
-$3.64
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-10.64%
Number of Analysts
18

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-0.55%
EPS (3 Months)
-9.84%

Next Earnings Summary

PRAX is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is -3.64 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
PRAX revenue by date.PRAX revenue by date.
2.447M8.553M
249.53%		40.8K
-100.00%		3.845M302.15M
7,758.26%		1.084B
258.76%		2.264B
108.86%		3.63B
60.34%		6.033B
66.20%		7.918B
31.24%		9.187B
16.03%
EBITDA
YoY % growth
PRAX ebitda by date.PRAX ebitda by date.
-213.57M
-27.77%		-125.941M
41.03%		-199.807M
-58.65%		-303.701M
-63.19%		-442.322M
-35.66%		-381.78M
13.69%		-109.468M
71.33%		263.54M
340.75%		869.37M
229.88%		548M
-36.97%		908.62M
65.81%		1.266B
39.33%
EBIT
YoY % growth
PRAX ebit by date.PRAX ebit by date.
-213.99M
-27.89%		-126.373M
40.94%		-200.165M
-58.39%		-313.858M
-62.96%		-445.919M
-36.70%		-340.365M
23.67%		257.16M
175.55%		1.291B
402.02%		2.363B
83.04%		3.904B
65.21%		4.919B
26.00%		5.638B
14.62%
Operating Margin
PRAX operating margin by date.PRAX operating margin by date.
N/A-5,164.41%-2,340.29%-769,260.50%-11,597.36%-112.65%23.72%57.02%65.10%64.71%62.12%61.37%
EPS
YoY % growth
PRAX eps by date.PRAX eps by date.
-69.90
-19.79%		-23.67
66.14%		-10.27
56.61%		-13.31
-31.06%		-15.16
-12.63%		-10.70
29.42%		4.87
145.48%		41.97
762.57%		70.64
68.30%		107.36
51.99%		125.11
16.53%		138.58
10.77%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-3.64
-10.64%		-3.74
-12.89%		-3.91
-16.50%		-3.91
-11.62%		-4.12
-13.12%		-3.73
0.10%		-2.96
24.43%		-1.47
62.40%
Revenue
Q2Q % growth		460.02K3.914M9.607M26.802M56.916M
12,272.51%		134.76M
3,343.03%
EBITDA
Q2Q % growth		-105.111M
-40.75%		-107.253M
-41.17%		-112.737M
-44.08%		-117.221M
-20.97%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-102.514M
-37.18%		-106.559M
-40.09%		-112.677M
-43.80%		-115.165M
-18.67%		-131.743M
-28.51%		-124.882M
-17.20%		-104.897M
6.91%		-66.769M
42.02%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50 -50 100

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
33.17%
EPS Next 5 Year
48.61%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
2,883.94%
Revenue Next 5 Year
876.90%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
18.20%
EBIT Next 5 Year
36.68%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PRAXIS PRECISION MEDICINES I / PRAX Forecast FAQ

What is the price target for PRAX stock?

22 analysts have analysed PRAX and the average price target is 646.92 USD. This implies a price increase of 99.54% is expected in the next year compared to the current price of 324.2.

When does PRAXIS PRECISION MEDICINES I (PRAX) report earnings?

PRAXIS PRECISION MEDICINES I (PRAX) will report earnings on 2026-05-13.

What are the consensus estimates for PRAXIS PRECISION MEDICINES I (PRAX) next earnings?

The consensus EPS estimate for the next earnings of PRAXIS PRECISION MEDICINES I (PRAX) is -3.64 USD and the consensus revenue estimate is 0 USD.

How do analysts rate PRAXIS PRECISION MEDICINES I (PRAX)?

The consensus rating for PRAXIS PRECISION MEDICINES I (PRAX) is 82.7273 / 100 . This indicates that analysts generally have a positive outlook on the stock.